Biotech and pharmaceutical companies should shelve the arrogance when applying for approval of new drugs or seeking the all clear to go ahead with clinical testing in the EU. EU’s medicines authorities, EMA, take offence to being looked down upon as a less important agency than the American FDA.
That is the advice offered by top advisor for the pharma and medtech industries, Steffen Thirstrup, advisory board member, NDA Regulatory Services, and former head of medicines approvals in Denmark.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app